CIK 0001827506
TRML Tourmaline Bio, Inc.
Insider trading from SEC Form 4. Last filing Sep 9, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Tourmaline Bio, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | Aaron Kantoff director | MOption exercise Common Stock | +37,890 | $0.13 | $4,926 | 83,281 | Sep 9, 2025 |
| Sep 5, 2025 | Aaron Kantoff director | MOption exercise Common Stock | +10,000 | $9.46 | $95k | 93,281 | Sep 9, 2025 |
| Sep 5, 2025 | Aaron Kantoff director | MOption exercise Stock Option (Right to Buy)derivative | -37,890 | $0.00 | $0 | 0 | Sep 9, 2025 |
| Sep 5, 2025 | Aaron Kantoff director | MOption exercise Stock Option (Right to Buy)derivative | -10,000 | $0.00 | $0 | 0 | Sep 9, 2025 |
| Jun 4, 2025 | Caley Castelein director | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
| Jun 4, 2025 | Aaron Kantoff director | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
| Jun 4, 2025 | Mark McDade director | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
| Jun 4, 2025 | Clay B Siegall director | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
| Jun 4, 2025 | Sapna Srivastava director | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
| Jun 4, 2025 | Parvinder Thiara director | AGrant or award Stock Option (Right to Buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 6, 2025 |
| Feb 3, 2025 | Sandeep Chidambar Kulkarni CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +226,000 | $0.00 | $0 | 226,000 | Feb 4, 2025 |
| Jan 27, 2025 | Kevin Bruce Johnson Chief Regulatory Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +58,000 | $0.00 | $0 | 58,000 | Jan 29, 2025 |
| Jan 27, 2025 | Susan Dana Jones Chief Technology Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +58,000 | $0.00 | $0 | 58,000 | Jan 29, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Caley Casteleindirector
- Kevin Bruce JohnsonChief Regulatory Officer
- Susan Dana JonesChief Technology Officer
- Aaron Kantoffdirector
- Sandeep Chidambar KulkarniCEO
- Mark McDadedirector
- Clay B Siegallceo, president, officer, director
- Sapna Srivastavadirector
- Parvinder Thiaradirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.